Calliditas Therapeutics AB (publ) (CALT) Set to Announce Earnings on Tuesday

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) is scheduled to announce its earnings results before the market opens on Tuesday, August 13th. Analysts expect the company to announce earnings of ($0.25) per share for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) last released its earnings results on Thursday, May 23rd. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.74). Calliditas Therapeutics AB (publ) had a negative net margin of 40.19% and a negative return on equity of 160.87%. The company had revenue of $28.43 million during the quarter, compared to analyst estimates of $35.78 million. On average, analysts expect Calliditas Therapeutics AB (publ) to post $-1 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Calliditas Therapeutics AB (publ) Stock Performance

Shares of NASDAQ CALT opened at $39.61 on Monday. The company has a debt-to-equity ratio of 8.46, a quick ratio of 2.62 and a current ratio of 2.69. The stock has a 50 day moving average price of $39.03 and a 200 day moving average price of $27.87. The stock has a market capitalization of $1.18 billion, a PE ratio of -21.41 and a beta of 1.77. Calliditas Therapeutics AB has a 52 week low of $15.25 and a 52 week high of $41.90.

Analysts Set New Price Targets

CALT has been the subject of several recent analyst reports. Stifel Nicolaus reissued a “hold” rating and issued a $40.00 price objective (down previously from $55.00) on shares of Calliditas Therapeutics AB (publ) in a report on Tuesday, May 28th. HC Wainwright reiterated a “neutral” rating and issued a $39.00 price target on shares of Calliditas Therapeutics AB (publ) in a research note on Tuesday, May 28th. Lifesci Capital downgraded shares of Calliditas Therapeutics AB (publ) from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 28th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $39.00 target price (down from $58.00) on shares of Calliditas Therapeutics AB (publ) in a report on Tuesday, May 28th. Finally, Citigroup reiterated a “neutral” rating and issued a $39.00 target price on shares of Calliditas Therapeutics AB (publ) in a research note on Friday, May 31st. Six equities research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $35.00.

About Calliditas Therapeutics AB (publ)

Calliditas Therapeutics AB (publ), a commercial-stage bio-pharmaceutical company, focused on identifying, developing, and commercializing novel treatments in orphan indications with an initial focus on renal and hepatic diseases with significant unmet medical needs in the United States, Europe, and Asia.